TP53 mutations in circulating tumor DNA for response monitoring in patients with high grade serous carcinoma of ovary

被引：0
|
作者：
Kim, Y. M. [1 ]
Lee, S. W. [1 ]
Lee, H. Y. [2 ]
Lee, S. E. [2 ]
Park, Y. R. [3 ]
Kim, J. H. [1 ]
Kim, Y. T. [1 ]
Nam, J. H. [1 ]
机构：
[1] Univ Ulsan, Coll Med, ASAN Med Ctr, Seoul, South Korea
[2] Asan Inst Life Sci, Seoul, South Korea
[3] Asan Med Ctr, Seoul, South Korea
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 137卷
关键词：
D O I：
10.1016/j.ygyno.2015.01.027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
25
引用
收藏
页码：12 / 13
页数：3
相关论文
共 50 条
  • [31] Most High Grade Serous Carcinomas Arising in Low Grade Serous Carcinomas Do Not Show Evidence of TP53 or BRAF Mutations
    Zarei, Shabnam
    Kerr, Sarah E.
    Wang, Yan
    Jenkins, Sarah M.
    Bell, Debra A.
    MODERN PATHOLOGY, 2016, 29 : 315A - 315A
  • [32] Most High Grade Serous Carcinomas Arising in Low Grade Serous Carcinomas Do Not Show Evidence of TP53 or BRAF Mutations
    Zarei, Shabnam
    Kerr, Sarah E.
    Wang, Yan
    Jenkins, Sarah M.
    Bell, Debra A.
    LABORATORY INVESTIGATION, 2016, 96 : 315A - 315A
  • [33] Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study
    Vang, Russell
    Levine, Douglas A.
    Soslow, Robert A.
    Zaloudek, Charles
    Shih, Ie-Ming
    Kurman, Robert J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2016, 35 (01) : 48 - 55
  • [34] Clinical utility of monitoring TP53 mutation (TP53m) circulating tumour DNA (ctDNA) in patients (pts) with high-grade ovarian carcinomas (HGOC)
    Kfoury, M.
    Bonnet, C.
    Delanoy, N.
    Leformal, A.
    Brizais, C.
    Howarth, K.
    Morris, C.
    Pautier, P.
    Colomba-Blameble, E.
    Gouy, S.
    Morice, P.
    Maulard, A.
    Elodie, L.
    Leary, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S632 - S632
  • [35] TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions
    Kuhn, Elisabetta
    Kurman, Robert J.
    Vang, Russell
    Sehdev, Ann Smith
    Han, Guangming
    Soslow, Robert
    Wang, Tian-Li
    Shih, Ie-Ming
    JOURNAL OF PATHOLOGY, 2012, 226 (03): : 421 - 426
  • [36] Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma
    Qiu, Chunping
    Wang, Yu
    Wang, Xiao
    Zhang, Qing
    Li, Yinuo
    Xu, Ying
    Jin, Chengjuan
    Bu, Hualei
    Zheng, Wenxin
    Yang, Xingsheng
    Lu, Nan
    Kong, Beihua
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (06) : 2041 - 2050
  • [37] Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression
    Holy, Petr
    Hlavac, Viktor
    Seborova, Karolina
    Susova, Simona
    Tesarova, Tereza
    Rob, Lukas
    Hruda, Martin
    Bouda, Jiri
    Bartakova, Alena
    Mrhalova, Marcela
    Kopeckova, Katerina
    Allah, Mohammad Al Obeed
    Spacek, Jiri
    Sedlakova, Iva
    Soucek, Pavel
    Vaclavikova, Radka
    INTERNATIONAL JOURNAL OF CANCER, 2024, 155 (01) : 104 - 116
  • [38] Targeting the DNA Damage Response in OSCC with TP53 Mutations
    Lindemann, A.
    Takahashi, H.
    Patel, A. A.
    Osman, A. A.
    Myers, J. N.
    JOURNAL OF DENTAL RESEARCH, 2018, 97 (06) : 635 - 644
  • [39] Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
    Kasherman, Lawrence
    Garg, Swati
    Tchrakian, Nairi
    Clarke, Blaise
    Karakasis, Katherine
    Kim, Raymond H.
    Stockley, Tracy L.
    Dhani, Neesha
    Oza, Amit M.
    Lheureux, Stephanie
    GYNECOLOGIC ONCOLOGY REPORTS, 2021, 36
  • [40] Studying the effect of germline polymorphisms on somatic hotspot mutations in TP53 for the treatment of high-grade serous ovarian carcinoma.
    de Souza, Cristabelle Madona N.
    Chien, Jeremy
    Madden, Jill
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 103 - 104
12345